INVESTOR PRESENTATION
NOVEMBER 2016
DESERT HOPE ALUMNI
INVESTOR PRESENTATION DESERT HOPE ALUMNI NOVEMBER 2016 IMPORTANT - - PowerPoint PPT Presentation
INVESTOR PRESENTATION DESERT HOPE ALUMNI NOVEMBER 2016 IMPORTANT PRESENTATION INFORMATION 2 We use market data and industry forecasts and projections throughout this presentation, including data from publicly available information and industry
DESERT HOPE ALUMNI
Notice to Investors
We use market data and industry forecasts and projections throughout this presentation, including data from publicly available information and industry publications. These sources generally state that the information they provide has been obtained from sources believed to be reliable, but that the accuracy and completeness of the information are not guaranteed. The forecasts and projections are based on industry surveys and the preparers’ experience in the industry, and there can be no assurance that any of the forecasts or projections will be achieved. We believe that the surveys and market research others have performed are reliable, but we have not independently investigated or verified this information. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and uncertainties as the other forward-looking statements contained in this presentation.
Forward-Looking Statements
Some of the statements made in this presentation constitute forward-looking statements within the meaning of federal securities laws. Forward-looking statements reflect our current views with respect to future events and performance. In some cases you can identify forward-looking statements by terminology such as “may,” “might, “will,” “should,” “could” or the negative thereof. Generally, the words “anticipate,” “believe,” “continues,” “expect,” “intend,” “estimate,” “project,” “plan” and similar expressions identify forward-looking statements. In particular, statements about our pipeline, industry growth opportunities, disclosure of key performance indicators, business growth strategy and financial guidance in this presentation are forward-looking statements. We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks, uncertainties and
performance or achievements expressed or implied by such forward-looking statements. For additional discussion of risks, uncertainties and other factors, see the section titled “Risk Factors” in our Annual Report on Form 10-K and other filings with the Securities and Exchange Commission (the "SEC"). Risks, uncertainties and other factors include, without limitation: (i) our inability to operate our facilities; (ii) our reliance on our sales and marketing program to continuously attract and enroll clients; (iii) a reduction in reimbursement rates by certain third-party payors for inpatient and outpatient services and point of care and definitive lab testing; (iv) our failure to successfully achieve growth through acquisitions and de novo expansions; (v) uncertainties regarding the timing of the closing of acquisitions; (vi) our failure to achieve anticipated financial results from prior acquisitions; (vii) the possibility that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the acquisitions; (viii) a disruption in our ability to perform definitive drug testing services; (ix) maintaining compliance with applicable regulatory authorities, licensure and permits to operate our facilities and lab; (x) a disruption in our business and reputation and potential economic consequences with the civil securities claims brought by shareholders; (xi) our inability to agree on conversion and other terms for the balance of convertible debt; (xii)
subordinated debt; (xiv) our inability to integrate newly acquired facilities; and (xv) general economic conditions, as well as other risks discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K and other filings with the SEC. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. These risks and uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. These forward-looking statements are made only as of the date
any such statements to reflect future events or developments.
Malibu, La Paloma in Memphis and Michael’s House in Palm Springs
national industry conferences
investment banking firm
Stephens Inc.
international VoIP Company
(since 2011)
(since 2013) michael@contactaac.com
(since 2011) kmanz@contactaac.com
Mississippi, Nevada, New Jersey and Texas
Texas
Laguna Treatment Hospital Desert Hope Forterus SDTC Greenhouse Headquarters Oxford River Oaks Recovery First Recovery First West Palm Sunrise House Ringwood* * Pending Solutions Recovery Townsend Sagenex Labs Addiction Labs Out-of-Network Residential Facility In-Network Residential Facility In-Network Outpatient Facility Out-of-Network Outpatient Facility Out-of-Network Laboratory In-Network Laboratory CSRI Sober Living Beds In/Out-of-Network Residential Facility In/Out-of-Network Outpatient Facility
Out-of-Network commercial reimbursements
72% Out-of-Network, 22% In-Network
in-network commercial insurance, private pay and possible government pay options
alone lab, lower acuity outpatient centers and a higher acuity hospital
centers, higher acuity hospital locations while diversifying its lab to include 3rd party
Individual 6% Out-of-Network 72% In-Network 22% Individual 8% Out-of-Network 92% Residential 94% Laboratory 6% Hospital 2% Residential 74% Outpatient 8% Laboratory 16%
PAYORS SERVICES
2015 - Q4 2016 - Q1 2016 - Q2 2016 - Q3 2016 - Q3 2016 - Q4 Senior Credit Facility $95,141 $93,088 $117,523 $139,426 $129,426 $139,426 Deerfield Convertible Debt $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 Deerfield Subordinated Debt $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 Total Debt $145,141 $143,088 $167,523 $189,426 $179,426 $189,426 Cash On Hand $18,750 $13,237 $7,269 $13,276 $13,276 $10,000 Net Debt $126,391 $129,851 $160,254 $176,150 $166,150 $176,150 Trailing 12 Months AEBITDA $44,277 $47,510 $45,610 $46,006 $46,006 $47,000 Senior Leverage (Net Debt) 2.15 1.68 2.42 2.74 2.52 2.75 Total Leverage (Net Debt) 2.85 2.73 3.51 3.83 3.61 3.82 Collateral Property and equipment, net $109,724 $111,972 $128,623 $136,171 $136,171 $136,171 Accounts receivable, net of allowances $60,934 $62,922 $74,692 $80,410 $80,410 $80,410 Cash $18,750 $13,237 $7,269 $13,276 $13,276 $10,000 Total Collateral $189,408 $188,131 $210,584 $229,857 $229,857 $226,581 Collateral Coverage 1.3 1.3 1.3 1.2 1.3 1.2
ABSENT CA MATTER PROJECTED
dollars in thousands
1,000 2,000 3,000 4,000
Q 1 ' 1 5 Q 2 ' 1 5 Q 3 ' 1 5 Q 4 ' 1 5 Q 1 ' 1 6 Q 2 ' 1 6 Q 3 ' 1 6
3,258 2,890 2,623 2,462 1,980 1,806 1,515
250 500 750 1,000
Q 1 ' 1 5 Q 2 ' 1 5 Q 3 ' 1 5 Q 4 ' 1 5 Q 1 ' 1 6 Q 2 ' 1 6 Q 3 ' 1 6
853 821 764 670 560 539 480
0MM 20MM 40MM 60MM
Q 1 ' 1 5 Q 2 ' 1 5 Q 3 ' 1 5 Q 4 ' 1 5 Q 1 ' 1 6 Q 2 ' 1 6 Q 3 ' 1 6
$48.2 $43.9 $43.6 $41.6 $37.8 $31.5 $27.6
5,000 10,000 15,000 20,000
Q 1 ' 1 5 Q 2 ' 1 5 Q 3 ' 1 5 Q 4 ' 1 5 Q 1 ' 1 6 Q 2 ' 1 6 Q 3 ' 1 6
15,299 13,079 4,978 4,328 4,329 2,634 1,588
0MM 1MM 2MM 3MM 4MM 5MM
Q 1 ' 1 5 Q 2 ' 1 5 Q 3 ' 1 5 Q 4 ' 1 5 Q 1 ' 1 6 Q 2 ' 1 6 Q 3 ' 1 6
$5.0 $4.0 $1.9 $1.7 $2.1 $2.1 $0.8
100 200 300 400 500
Q 1 ' 1 5 Q 2 ' 1 5 Q 3 ' 1 5 Q 4 ' 1 5 Q 1 ' 1 6 Q 2 ' 1 6 Q 3 ' 1 6
432 381 153 160 127 60 14
3 enzymatic immunoassay machines (EIA) - toxicology, general clinical testing 1 polymerase chain reaction machine (PCR) - DNA
Desert Hope / Greenhouse
($80K per sober living bed versus $125K residential bed)
residential admit
annual outpatient revenue
DSO Roll Up 2015 - Q4 2016 - Q1 2016 - Q2 2016 - Q3 Legacy1 78 76 79 77 Acquisitions / De Novo2 1 4 2 5 Professional Group’s / Other
Lab 20 14 14 24 Total 96 88 95 105
1Greenhouse; Desert Hope; Forterus, San Diego; Singer Island; Greenhouse Outpatient Center; Desert Hope Outpatient Center, Recovery First; CSRI; Sunrise 2River Oaks; Laguna; Oxford; Townsend; Sagenex; Solutions Recovery
Days Sales Outstanding = quarter end Accounts Receivable balance, Net of Provision divided by Average Daily Sales (Net Revenue for the quarter divided by number of days in period)
Q1-FY15 Q2-FY15 Q3-FY15 Q4-FY15 Q1-FY16 Q2-FY16 Q3-FY16 Client Revenue $42,822,645 $53,784,428 $53,694,831 $55,450,126 $62,408,786 $68,161,910 $68,491,512 ADC 480 539 560 670 764 821 853 Admits 1,588 1,806 1,980 2,462 2,623 2,890 3,258 Employees 986 1,126 1,501 1,766 1,756 2,185 2,107 Corp Overhead $6,877,238 $7,126,099 $8,264,184 $8,876,363 $11,082,490 $11,431,715 $9,690,994 % of Client Revenue 16.1% 13.2% 15.4% 16.0% 17.8% 16.8% 14.1% Cost Per ADC $14,328 $13,221 $14,757 $13,248 $14,506 $13,924 $11,361 Cost Per Admit $4,331 $3,947 $4,174 $3,605 $4,225 $3,956 $2,975 Cost Per Employee $6,975 $6,329 $5,506 $5,026 $6,311 $5,233 $4,599 CRMS Billing Expenses $890,887 $1,036,878 $1,221,359 $1,132,630 $1,745,098 $1,506,602 $1,599,724 % of Client Revenue 2.1% 1.9% 2.3% 2.0% 2.8% 2.2% 2.3% Sales & Marketing, Net of RB Revenue1 $8,560,808 $9,367,644 $8,844,859 $8,926,730 $9,282,308 $11,355,454 $11,636,555 Cost Per Admit $5,391 $5,188 $4,467 $3,626 $3,539 $3,929 $3,572
1Includes SW&B for business development, call center, Recovery Brands, Taj Media, and corporate marketing departments LESS revenue generated from Recovery Brands
(4 largest players < 10% market share (1))
(1) 2015 IBISWorld (2) Centers for Disease Control and Prevention (3) For nine months ended September 30, 2016
Adjusted EBITDA, adjusted net income available to AAC Holdings, Inc. stockholders, and adjusted diluted earnings per share (herein collecYvely referred to as “Non-GAAP Disclosures”) are “non-GAAP financial measures” as defined under the rules and regulaYons promulgated by the SEC. Management defines Adjusted EBITDA as net income adjusted for interest expense, depreciaYon and amorYzaYon expense, income tax expense, stock-based compensaYon and related tax reimbursements, liYgaYon se_lement and California ma_er related expense, acquisiYon-related expense (which includes professional services for accounYng, legal, valuaYon services and licensing expenses), de novo start-up expenses, facility closure operaYng losses and expense associated with The Academy and FitRx in the fourth quarter of 2015, and bargain purchase gain associated with our acquisiYon of Sunrise House in the fourth quarter of 2015. Management defines Adjusted Net Income Available to AAC Holdings, Inc. stockholders as net income available to AAC Holdings, Inc. stockholders adjusted for liYgaYon se_lement and California ma_er related expense, acquisiYon-related expense (which includes professional services for accounYng, legal, valuaYon services and licensing expenses), de novo start-up expenses, facility closure operaYng losses and expense associated with The Academy and FitRx, bargain purchase gain associated with our acquisiYon of Sunrise House in the fourth quarter
The Non-GAAP Disclosures are considered supplemental measures of the Company’s performance and are not required by, or presented in accordance with, generally accepted accounYng principles, or GAAP. The Non-GAAP Disclosures are not measures of the Company’s financial performance under GAAP and should not be considered as an alternaYve to net income or any
by certain investors as a measure of a company’s historical performance. Management believes these measures are frequently used by securiYes analysts, investors and other interested parYes in the evaluaYon of issuers of equity securiYes, many of which present EBITDA, Adjusted EBITDA and Adjusted EPS when reporYng their results. Because Non-GAAP Disclosures are not determined in accordance with GAAP, they are subject to varying calculaYons and may not be comparable to similarly Ytled measures of other companies. Management’s presentaYon of Non-GAAP Disclosures should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.
September 30, 2016 June 30, 2016 March 31, 2016 December 31, 2015
Net (loss) income $ (5,076) $ 679 $ 5,953 $ 8,341 Non-GAAP Adjustments: Interest expense 7,031 6,307 4,568 3,607 Depreciation and amortization 15,669 12,961 10,412 7,837 Income tax (benefit) expense (1,108) 294 3,415 4,780 Stock-based compensation and related tax reimbursements 8,452 7,658 6,762 5,757 Litigation settlement and California matter related expense 9,275 7,562 # 7,751 # 5,446 Acquisition-related expense 3,606 3,979 # 3,663 # 3,801 De novo start-up expense and other 8,045 5,474 4,231 3,369 Facility closure operating losses and expense 1,887 2,471 2,530 3,114 Bargain purchase gain (1,775) (1,775) (1,775) (1,775) Adjusted EBITDA $ 46,006 $ 45,610 $ 47,510 $ 44,277
Trailing Twelve Months Ended
AAC HOLDINGS, INC. SUPPLEMENTAL RECONCILIATION OF NON-GAAP DISCLOSURES Unaudited Reconciliation of Trailing Twelve Months (TTM) Adjusted EBITDA to Net Income (Loss)